1 序文
2 範囲と方法論
2.1 本調査の目的
2.2 利害関係者
2.3 データソース
2.3.1 一次ソース
2.3.2 二次ソース
2.4 市場推定
2.4.1 ボトムアップ・アプローチ
2.4.2 トップダウン・アプローチ
2.5 予測方法論
3 エグゼクティブサマリー
4 はじめに
4.1 概要
4.2 主な業界トレンド
5 世界のデジタル式定量噴霧式吸入器市場
5.1 市場概要
5.2 市場実績
5.3 COVID-19 の影響
5.4 市場予測
6 タイプ別市場内訳
6.1 ブランド薬
6.1.1 市場動向
6.1.2 市場予測
6.2 ジェネリック薬
6.2.1 市場動向
6.2.2 市場予測
7 製品別市場内訳
7.1 定量噴霧式吸入器
7.1.1 市場動向
7.1.2 市場予測
7.2 ドライパウダー吸入器
7.2.1 市場動向
7.2.2 市場予測
8 地域別市場
8.1 北米
8.1.1 米国
8.1.1.1 市場動向
8.1.1.2 市場予測
8.1.2 カナダ
8.1.2.1 市場動向
8.1.2.2 市場予測
8.2 アジア太平洋地域
8.2.1 中国
8.2.1.1 市場動向
8.2.1.2 市場予測
8.2.2 日本
8.2.2.1 市場動向
8.2.2.2 市場予測
8.2.3 インド
8.2.3.1 市場動向
8.2.3.2 市場予測
8.2.4 韓国
8.2.4.1 市場動向
8.2.4.2 市場予測
8.2.5 オーストラリア
8.2.5.1 市場動向
8.2.5.2 市場予測
8.2.6 インドネシア
8.2.6.1 市場動向
8.2.6.2 市場予測
8.2.7 その他
8.2.7.1 市場動向
8.2.7.2 市場予測
8.3 欧州
8.3.1 ドイツ
8.3.1.1 市場動向
8.3.1.2 市場予測
8.3.2 フランス
8.3.2.1 市場動向
8.3.2.2 市場予測
8.3.3 英国
8.3.3.1 市場動向
8.3.3.2 市場予測
8.3.4 イタリア
8.3.4.1 市場動向
8.3.4.2 市場予測
8.3.5 スペイン
8.3.5.1 市場動向
8.3.5.2 市場予測
8.3.6 ロシア
8.3.6.1 市場動向
8.3.6.2 市場予測
8.3.7 その他
8.3.7.1 市場動向
8.3.7.2 市場予測
8.4 ラテンアメリカ
8.4.1 ブラジル
8.4.1.1 市場動向
8.4.1.2 市場予測
8.4.2 メキシコ
8.4.2.1 市場動向
8.4.2.2 市場予測
8.4.3 その他
8.4.3.1 市場動向
8.4.3.2 市場予測
8.5 中東およびアフリカ
8.5.1 市場動向
8.5.2 国別の市場内訳
8.5.3 市場予測
9 SWOT分析
9.1 概要
9.2 強み
9.3 弱み
9.4 機会
9.5 脅威
10 価値連鎖分析
11 ポーターのファイブフォース分析
11.1 概要
11.2 買い手の交渉力
11.3 売り手の交渉力
11.4 競争の度合い
11.5 新規参入の脅威
11.6 代替品の脅威
12 価格分析
13 競合状況
13.1 市場構造
13.2 主要企業
13.3 主要企業のプロフィール
3M Company
AstraZeneca plc
GlaxoSmithKline plc
Glenmark Pharmaceuticals Limited
H&T Presspart Manufacturing Ltd
Koninklijke Philips N.V
Lupin Limited
Novartis AG
OPKO Health Inc
Propeller Health (ResMed)
Sensirion AG Switzerland
Teva Pharmaceutical Industries Ltd
A digital dose inhaler (DDI) is used for delivering medication to individuals suffering from respiratory ailments like asthma or chronic obstructive pulmonary disease (COPD). It comprises built-in sensors and electronic features that can record when the medication is administered and the quantity of the dose. It assists in ensuring adherence to prescribed treatment routines and allowing for a better understanding of the disease of the patient and the effectiveness of the medication. As it provides feedback to the users and helps them to correct their technique, the demand for DDI is rising across the globe.
At present, the increasing adoption of DDIs, as they offer enhanced convenience and effectiveness in medication delivery, is bolstering the growth of the market. Besides this, the growing demand for efficient and effective inhalation devices among patients is offering a positive market outlook. In line with this, the rising adoption of DDIs among the geriatric population, as they are more prone to respiratory issues, is propelling the market growth. Apart from this, the increasing utilization of DDIs, as they make treatment more transparent and potentially more effective, is contributing to the market growth. Furthermore, the integration of artificial intelligence (AI) in DDIs to enable enhanced monitoring of medication usage and provide real-time feedback to patients is strengthening the market growth. Moreover, the increasing focus on personalized medicines among individuals is supporting the market growth.
Digital Dose Inhaler Market Trends/Drivers:
Increasing prevalence of chronic respiratory diseases
The rising prevalence of chronic respiratory diseases (CRDs), such as asthma and chronic obstructive pulmonary disease (COPD), among the masses worldwide is contributing to the market growth. In addition, there is an increase in the demand for enhanced drug delivery systems among individuals requiring management of their respiratory conditions. Apart from this, DDIs offer a modern solution by ensuring accurate dosage and providing feedback on usage to both patients and healthcare providers, which is offering a positive market outlook. In line with this, the data collected can be instrumental in personalizing treatment plans, improving adherence to medication regimes, and potentially reducing hospitalizations related to CRDs.
Technological advancements for real time adjustments
Various companies are continuously advancing their DDIs to provide enhanced care and satisfaction to patients. They offer features, such as dose counting, adherence monitoring, and data transmission, to healthcare providers. In line with this, these features promote better disease management, allow for real-time adjustments to treatment plans, and ensure that patients are effectively adhering to their medication schedules, which is offering a favorable market outlook. Apart from this, the technology in DDIs can provide immediate feedback to patients on their inhalation technique, which is crucial for the effectiveness of the treatment. As a result, these advancements are enhancing the quality of respiratory care for patients suffering from severe respiratory disorders.
Growing focus on chronic respiratory disease management
The rising focus on chronic respiratory disease (CRD) management among individuals and healthcare providers is contributing to the growth of the market. In line with this, there is an increase in the demand for more efficient and effective management of CRDs. Apart from this, DDIs can monitor medication adherence and provide actionable feedback, which plays a crucial role in the broader strategy of chronic respiratory disease management. In addition, they enable healthcare providers to have better insights into patient adherence and disease progression, facilitating timely interventions and potentially better outcomes for patients. Furthermore, the rising adoption of DDIs, as they promote better self-management, is propelling the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on type and product.
Breakup by Type:
Branded Medication
Generics Medication
Branded medication accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes branded medication and generics medication. According to the report, branded medication represented the largest segment. Branded medication refers to drugs that are developed and marketed by pharmaceutical companies under a proprietary name. These medications are often the first of their kind to be introduced to the market and are protected by patents, preventing other companies from selling generic versions for a certain period. The development of branded medications involves thorough research and development (R&D) activities to ensure their efficacy, safety, and quality. Pharmaceutical companies are investing significantly in (R&D) to develop new respiratory medications, which are then sold under a brand name, often at a higher price point due to the innovation and research backing them.
Breakup by Product:
Metered Dose Inhaler
Dry Powder Inhaler
Metered dose inhaler holds the largest share in the industry
A detailed breakup and analysis of the market based on the product has also been provided in the report. This includes metered dose inhaler and dry powder inhaler. According to the report, metered dose inhaler accounted for the largest market share. Metered dose inhalers (MDIs) are one of the most common types of inhalers used in respiratory therapy. They are designed to deliver a specific amount of medication to the lungs, with each actuation or press of the inhaler. MDIs consist of a pressurized canister that contains medication in a liquid or aerosol form, housed within a plastic case with a mouthpiece. When the inhaler is actuated, it releases a measured dose of medication in aerosol form for inhalation. MDIs are popular due to their portability, ease of use, and the ability to provide quick relief in acute respiratory situations. They are highly effective for delivering bronchodilators and steroids which are commonly used in the management of conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD).
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest digital dose inhaler market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share due to the increasing adoption of advanced respiratory devices. Additionally, the presence of well-established pharmaceutical and medical device companies is offering a positive market outlook. Apart from this, the rising focus on improving respiratory care solutions is contributing to the growth of the market. In addition, increasing incidences of respiratory disorders among individuals are propelling the growth of the market.
Competitive Landscape:
Various companies are investing in research and development (R&D) activities to create DDIs with enhanced features, such as improved dose counting, adherence monitoring, and real-time feedback mechanisms, to cater to the needs of patients and healthcare providers. Apart from this, companies are engaging in collaborations and partnerships to expand their technological capabilities and market reach. In line with this, they are providing more user-friendly and effective solutions for managing respiratory diseases. Besides this, major manufacturers are working on specialized inhaler solutions that are tailored to deliver complex biologics. Furthermore, companies are engaging in marketing and awareness campaigns to educate healthcare providers and patients about the advantages of digital dose inhalers over traditional ones.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
3M Company
AstraZeneca plc
GlaxoSmithKline plc
Glenmark Pharmaceuticals Limited
H&T Presspart Manufacturing Ltd.
Koninklijke Philips N.V.
Lupin Limited
Novartis AG
OPKO Health Inc.
Propeller Health (ResMed)
Sensirion AG Switzerland
Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global digital dose inhaler market in 2024?
2. What is the expected growth rate of the global digital dose inhaler market during 2025-2033?
3. What are the key factors driving the global digital dose inhaler market?
4. What has been the impact of COVID-19 on the global digital dose inhaler market?
5. What is the breakup of the global digital dose inhaler market based on the type?
6. What is the breakup of the global digital dose inhaler market based on the product?
7. What are the key regions in the global digital dose inhaler market?
8. Who are the key players/companies in the global digital dose inhaler market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Digital Dose Inhaler Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Branded Medication
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Generics Medication
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Product
7.1 Metered Dose Inhaler
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Dry Powder Inhaler
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 3M Company
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 AstraZeneca plc
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 GlaxoSmithKline plc
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.4 Glenmark Pharmaceuticals Limited
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 H&T Presspart Manufacturing Ltd.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.6 Koninklijke Philips N.V.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Lupin Limited
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.8 Novartis AG
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 OPKO Health Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.10 Propeller Health (ResMed)
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.11 Sensirion AG Switzerland
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.12 Teva Pharmaceutical Industries Ltd.
13.3.12.1 Company Overview
13.3.12.2 Product Portfolio
13.3.12.3 Financials
*** デジタル式吸入器の世界市場に関するよくある質問(FAQ) ***
・デジタル式吸入器の世界市場規模は？
→IMARC社は2024年のデジタル式吸入器の世界市場規模を38億米ドルと推定しています。
・デジタル式吸入器の世界市場予測は？
→IMARC社は2033年のデジタル式吸入器の世界市場規模を118億米ドルと予測しています。
・デジタル式吸入器市場の成長率は？
→IMARC社はデジタル式吸入器の世界市場が2025年～2033年に年平均12.1%成長すると展望しています。
・世界のデジタル式吸入器市場における主要プレイヤーは？
→「3M Company, AstraZeneca plc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Koninklijke Philips N.V., Lupin Limited, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG Switzerland, Teva Pharmaceutical Industries Ltd.など ...」をデジタル式吸入器市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
